{'52WeekChange': -0.23215228,
 'SandP52WeekChange': 0.0644362,
 'address1': '8000 Marina Boulevard',
 'address2': 'Suite 300',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 14.68,
 'askSize': 2200,
 'averageDailyVolume10Day': 877000,
 'averageVolume': 1129758,
 'averageVolume10days': 877000,
 'beta': 0.957337,
 'beta3Year': None,
 'bid': 14.34,
 'bidSize': 3200,
 'bookValue': 3.604,
 'category': None,
 'circulatingSupply': None,
 'city': 'Brisbane',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 14.88,
 'dayLow': 14.23,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -2.65,
 'enterpriseToRevenue': 1268.765,
 'enterpriseValue': 729540032,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '650 616 0075',
 'fiftyDayAverage': 17.081285,
 'fiftyTwoWeekHigh': 37,
 'fiftyTwoWeekLow': 10.09,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 42711189,
 'forwardEps': -2.83,
 'forwardPE': -5.1307425,
 'fromCurrency': None,
 'fullTimeEmployees': 362,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.20857,
 'heldPercentInstitutions': 0.82846,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/aimmune.com',
 'longBusinessSummary': 'Aimmune Therapeutics, Inc., a clinical-stage '
                        'biopharmaceutical company, develops and '
                        'commercializes product candidates for the treatment '
                        'of peanut and other food allergies. Its lead '
                        'Characterized Oral Desensitization ImmunoTherapy '
                        '(CODIT) product candidate is AR101, an '
                        'investigational biologic, which is in Phase III '
                        'clinical trial for the treatment of patients with '
                        'peanut allergy. The company also engages in the '
                        'research and development of AR201, a CODIT product '
                        'candidate for the treatment of egg allergy in '
                        'pediatric and young adult patients; and other CODIT '
                        'product candidates targeting food allergies, such as '
                        "cow's milk allergy. Aimmune Therapeutics, Inc. has a "
                        'strategic collaboration with an affiliate of Nestle '
                        'Health Science US Holdings, Inc. for the advancement '
                        'of food allergy therapeutics; and clinical '
                        'collaboration agreement with Regeneron Ireland '
                        'Unlimited Company and Sanofi Biotechnology SAS to '
                        'study AR101 with adjunctive dupilumab in '
                        'peanut-allergic patients in a Phase II trial. The '
                        'company was formerly known as Allergen Research '
                        'Corporation and changed its name to Aimmune '
                        'Therapeutics, Inc. in May 2015. Aimmune Therapeutics, '
                        'Inc. was founded in 2011 and is headquartered in '
                        'Brisbane, California.',
 'longName': 'Aimmune Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 947441664,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_241653204',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -280663008,
 'nextFiscalYearEnd': 1640908800,
 'open': 14.63,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.1,
 'phone': '650 614 5220',
 'previousClose': 14.81,
 'priceHint': 2,
 'priceToBook': 4.0288568,
 'priceToSalesTrailing12Months': 1647.7246,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 14.88,
 'regularMarketDayLow': 14.23,
 'regularMarketOpen': 14.63,
 'regularMarketPreviousClose': 14.81,
 'regularMarketPrice': 14.63,
 'regularMarketVolume': 935609,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 65250800,
 'sharesPercentSharesOut': 0.2906,
 'sharesShort': 18960735,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 17918817,
 'shortName': 'Aimmune Therapeutics, Inc.',
 'shortPercentOfFloat': 0.4114,
 'shortRatio': 14.39,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'AIMT',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -4.442,
 'twoHundredDayAverage': 20.303308,
 'volume': 935609,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.aimmune.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94005'}